Auro Laboratories Share Price | Auro Laboratories Stock Screener
AUROLAB
Pharmaceuticals
Share Price BSE
₹254.50
▲
2.95 (1.17%)
As of June 22, 2026, the Auro Laboratories share price (BSE: AUROLAB) is ₹254.50, up 1.17% from the previous close, with shares trading between ₹248.00 and ₹266.95, and a 52-week range of ₹179.25–₹302.05.
Check AUROLAB 52-week performance for the annual price range and momentum.
Use the Auro Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Auro Laboratories Market Cap
₹160.10 Cr.
AUROLAB P/E Ratio (TTM)
85.27
Auro Laboratories P/B Ratio
3.65
EPS (TTM)
₹5.67
Dividend Yield
-
Debt to Equity
0.81
AUROLAB 52 Week High
₹302.05
Auro Laboratories 52 Week Low
₹179.25
Operating Margin
1.00%
Profit Margin
-
AUROLAB Revenue (TTM)
₹3.00
EBITDA
-
Net Income
-
Total Assets
₹121.00
Total Equity
₹46.00
Auro Laboratories Share Price Chart
Screen Auro Laboratories share price with an interactive chart. Analyse AUROLAB price trends and volatility across different timeframes.
Auro Laboratories Company Profile - Fundamental Screener
Screen Auro Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AUROLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE292C01011
Auro Laboratories Balance Sheet Screener
Screen AUROLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 121 | 99 | 86 | 56 | 55 | 42 | 32 | 34 | 30 | 27 |
| Current Assets | 31 | 22 | 31 | 36 | 38 | 28 | 18 | 19 | 16 | 14 |
| Fixed Assets | 90 | 21 | 22 | 13 | 14 | 14 | 14 | 15 | 13 | 13 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 46 | 35 | 20 | 4 | 3 | 4 | 5 | 10 | 11 | 11 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 46 | 43 | 42 | 34 | 32 | 29 | 22 | 17 | 13 | 9 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 40 | 37 | 36 | 28 | 25 | 22 | 15 | 11 | 7 | 3 |
Auro Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Auro Laboratories income statement and profit fundamentals.
Analyze AUROLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Auro Laboratories share price evaluation.
| Item | 2025-Jun | 2025-Sept | 2024-Jun | 2024-Sept |
|---|---|---|---|---|
| Revenue | 3 | 10 | 6 | 3 |
| Expenses | 3 | 7 | 4 | 2 |
| EBITDA | 0 | 3 | 2 | 1 |
| Operating Profit % | 1.00% | 27.00% | 23.00% | 23.00% |
| Depreciation | 0 | 1 | 0 | 0 |
| Interest | 0 | 1 | 0 | 0 |
| Profit Before Tax | 0 | 2 | 1 | 1 |
| Tax | 0 | 1 | 0 | 0 |
| Net Profit | 0 | 1 | 1 | 0 |
| EPS | -0.17 | 1.15 | 1.21 | 0.57 |
Auro Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen AUROLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 6 | 19 | 3 | -7 | 13 | 9 | 7 | 6 | 7 | 8 |
| Investing Activities | -25 | -39 | -5 | -5 | -4 | -2 | -3 | -3 | -2 | -2 |
| Financing Activities | 18 | 19 | -8 | 10 | -1 | -6 | -2 | -2 | -4 | -5 |
| Net Cash Flow | -1 | -1 | -10 | -2 | 9 | 2 | 2 | 1 | 1 | 0 |
Auro Laboratories Shareholding Pattern Screener
See Auro Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Auro Laboratories promoter holding and ownership changes for AUROLAB on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 52.18% | 52.18% | 52.18% | 52.18% | 52.18% | 52.15% | 52.15% | 52.15% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 36.28% | 36.26% | 36.35% | 36.42% | 36.57% | 36.15% | 35.03% | 35.33% |
| Other Holding | 11.54% | 11.56% | 11.47% | 11.40% | 11.25% | 11.69% | 12.81% | 12.52% |
| Shareholder Count | 8,405 | 8,640 | 8,860 | 8,916 | 9,102 | 9,265 | 9,441 | 9,335 |
Auro Laboratories Share Dividend Screener - Share Yield Analysis
Check Auro Laboratories dividend history with payout and yield data.
View Auro Laboratories dividend details including ex-dates and amounts for AUROLAB stock.
Auro Laboratories Stock Index Membership
See which indices include Auro Laboratories stock.
Check AUROLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Auro Laboratories Market Events Screener - Corporate Actions
Get Auro Laboratories corporate actions including splits, bonuses, and buybacks.
Check Auro Laboratories stock events that may affect AUROLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -2.73% | ||
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 0.89% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 22.56% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -2.46% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -3.89% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 0.06% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -2.41% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | -0.22% |
| 2024-06-28 | 2024-06-28 | Annual General Meeting | NA | -13.67% |
Auro Laboratories Competitors Screener - Peer Comparison
Screen AUROLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 443,541 | 38.30 | 58,220 | 6.38% | 11,565 | 59.20 |
| Divis Laboratories | 178,660 | 69.69 | 10,560 | 8.73% | 2,520 | 55.09 |
| Torrent Pharmaceuticals | 150,574 | 70.06 | 13,886 | 20.34% | 2,138 | 50.44 |
| Cipla | 113,631 | 28.32 | 29,045 | 2.24% | 3,870 | 43.59 |
| Dr Reddys Laboratories | 107,644 | 25.53 | 33,593 | -0.44% | 3,998 | 45.29 |
| Zydus Life Science | 107,466 | 21.03 | 26,720 | 13.65% | 5,242 | 55.72 |
| Lupin | 107,455 | 20.08 | 27,488 | 19.98% | 5,345 | 62.62 |
| Mankind Pharma | 101,009 | 51.51 | 14,278 | 12.03% | 1,750 | 56.36 |
| Aurobindo Pharma | 86,208 | 24.84 | 33,385 | 3.21% | 3,376 | 59.92 |
| Laurus Labs | 77,183 | 85.73 | 6,868 | 22.01% | 890 | 63.84 |
Auro Laboratories Company Announcements - News Screener
Screen AUROLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-29 | Results For The Year Ended March 31 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Held On May 29 2026 | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | - |
| 2026-05-25 | Board Meeting Intimation for Board Meeting To Be Held On May 29 2026 | - |
| 2026-05-05 | Receipt Of Certification Of Substances Department From European Directorate For The Quality Of Medicines & Healthcare (EDQM) | - |
| 2026-05-05 | Receipt Of Certificate Of GMP Compliance Of A Manufacturer From Swissmedic Swiss Agency For Therapeutic Products. | - |
| 2026-04-14 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-02-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-05 | Financial Results For The Quarter Ended December 31 2025 | - |
| 2026-02-05 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-01-28 | Board Meeting Intimation for Unaudited Financial Results For Quarter Ended December 31 2025. | - |
| 2026-01-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-26 | Closure of Trading Window | - |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-12 | Grant Of Certificate Of Good Manufacturing Practices From World Health Organisation (WHQ"). | - |